Lazurite, Formally Indago Announces $10 Million Financing Close

HRS Scientific Sessions: Boston Scientific LBCT

During the Heart Rhythm Scientific Sessions this week, Boston Scientific announced positive LBCT data underscoring the safety and efficacy of multi-site pacing (MSP) over conventional cardiac resynchronization therapy (CRT), as well as poster presentations on real-world use of the WATCHMAN Left Atrial Appendage Closure (LAAC) device and next-generation WATCHMAN FLX LAAC device as alternatives to oral anticoagulation therapy for stroke risk reduction in patients with non-valvular atrial fibrillation.

What are the Most Commonly Performed Surgeries?

Whether you are trying to learn more about a surgery you are planning to have or find out what the most common procedures are, this list is here for you. Read more.

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

Lazurite, formally Indago, is a medical device and technology company. Today they announced the successful close of its $10 million convertible note round of financing.

The funds will be used to complete pre-submission testing of the ArthroFree™ – the company’s transformative wireless camera system — and to submit the device for FDA clearance, as well as continuing to develop a diverse pipeline of additional products and expand the company’s intellectual property portfolio.

The company plans to submit its 510(k) premarket notification in late 2021 and expects to receive FDA approval to launch the product in the first half of 2022.

The company also announced that it is changing its name to Lazurite Holdings, effective immediately.

“We are excited to have closed the financing round and look forward to using the funds to help move ArthroFree through the FDA and continuing the development of our suite of follow-on products,” said Eugene Malinskiy, Chief Executive Officer and founder. “With the close of the financing round, we also are excited to announce the company’s new name and to welcome Michael Salerno to our Board. Michael’s depth of knowledge and experience in capital raising in the health care company space will be invaluable to us as we continue to grow Lazurite and expand our product base.”

He continued, “Our novel and patented Meridiem™ light engine technology is one of our core assets. It is the basis for our ArthroFree wireless arthroscopic camera system as well as a number of other products in our pipeline. When people see or hear the name Lazurite™ — which references the color of the light emitted from the laser diode in our low-heat, high power light engine technology – we would like them to think of us as the medical device and innovations company known for its transformative surgical wireless platform, laser-based lighting and other advanced technologies.”

Salerno is a co-founder of AUA Capital Management and is formerly the managing director of QFS Asset Management, a premier global alternative asset manager specializing in quantitative investment strategies. He also is a former general partner of Select Capital Ventures, a fund focused on providing growth capital to health care-oriented companies. AUA Capital Management is the lead investor in the latest round of financing.

“I am delighted to join both the Board of Managers of Lazurite and the group of investors backing the company,” Salerno said. “I have been impressed to see how excited physicians are about ArthroFree and am impressed that more than 50 physicians are invested in Lazurite.”

Mark Froimson, MD, Chair of the Board of Managers of Lazurite, said, “We are very pleased to have completed another successful capital raise and to welcome Michael Salerno to our Board. His experience leading a venture cap fund focused on health care-oriented companies will be particularly valuable. We are looking forward to showcasing our products and the upcoming FDA submission.”



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.